SCI Pharmtech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 09, 2022
Share
SCI Pharmtech, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 181.36 million compared to TWD 176.57 million a year ago. Revenue was TWD 181.36 million compared to TWD 176.57 million a year ago. Net income was TWD 140.34 million compared to TWD 3.75 million a year ago. Basic earnings per share from continuing operations was TWD 1.3067 compared to TWD 0.0356 a year ago. Diluted earnings per share from continuing operations was TWD 1.3067 compared to TWD 0.0356 a year ago.
For the six months, sales was TWD 369.38 million compared to TWD 500.2 million a year ago. Revenue was TWD 369.38 million compared to TWD 500.2 million a year ago. Net income was TWD 181.52 million compared to TWD 45.42 million a year ago. Basic earnings per share from continuing operations was TWD 1.6889 compared to TWD 0.4267 a year ago. Diluted earnings per share from continuing operations was TWD 1.6889 compared to TWD 0.4178 a year ago.
SCI Pharmtech, Inc. is a Taiwan-based company principally engaged in the processing, manufacture and sales of Active Pharmaceutical Ingredients (APIs). The Company's main products include APIs, API intermediates and special and precision chemicals. The Company distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
SCI PHARMTECH, INC. 
